Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Plaque Psoriasis
Interventions: ILV-095 300 mg in a 4 to 1 ratio; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Miami Gardens, Florida • South Miami, Florida • Indianapolis, Indiana + 3 more

Conditions: HIV-1-infection
Interventions: TMB-365; Biological
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • Ft. Pierce, Florida • Orlando, Florida + 2 more

Conditions: Renal Impairment
Interventions: OTAMIXABAN (XRP0673); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Miami Gardens, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more

Conditions: Atopic Dermatitis (AD)
Interventions: Dupilumab, Placebo, Background treatment; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Dallas, Texas

Conditions: Gout
Interventions: RDEA3170; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Anesthesia
Interventions: Thoracic epidural block, Electrical Nerve stimulation, Solution For Thoracic epidural block; Procedure · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Stress
Interventions: MindBreaks - Audio-visual, MindBreaks - Auditory-only, MindBreaks - Visual-only; Behavioral
Lead sponsor: Well Living Lab, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypersensitivity
Interventions: ArteFill® Skin Test; Device
Lead sponsor: Suneva Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Non-Small Cell Lung Cancer
Interventions: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 6
States / cities: Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: ADHD
Interventions: NRCT-101SR, NRCT-202XR; Drug
Lead sponsor: Neurocentria, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 5
States / cities: Maitland, Florida • Decatur, Georgia • Savannah, Georgia + 2 more

Conditions: Dizziness
Interventions: PAS Goggle; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Renal Impairment
Interventions: AGO178C; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Healthy
Interventions: Sumatriptan succinate; Drug
Lead sponsor: NuPathe Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
Interventions: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion; Drug
Lead sponsor: Aptose Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 12 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Ketamine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 14 Years to 22 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Sertraline and Elzasonan Combination, Sertraline, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Beverly Hills, California • Norwich, Connecticut • New York, New York + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Ortho-Cyclen, Dulaglutide; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sjogren's Syndrome, Sjögren, Sjögren Syndrome, Unspecified
Interventions: R-2487; Drug
Lead sponsor: Rise Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Substance Abuse Problem
Interventions: Women-Only; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 291 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma in Children
Interventions: MERV 13 filter, Sham filter; Other
Lead sponsor: University of Washington; Other
Eligibility: 6 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: End-Stage Renal Disease, Gut Microbiome Dysbiosis
Interventions: p-inulin; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Mild-to-moderate COVID-19
Interventions: KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 16
States / cities: Hot Springs, Arkansas • Riverside, California • San Diego, California + 12 more

Conditions: Healthy
Interventions: TR-701 600mg; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Mild, Moderate and Severe Renal Impairment Study

Loss of Resistance, w/wo Stimulation, For Epidural Placement

Acute Stress Recovery

Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Vestibular Testing: Consistency and Effects Over Time

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)

Absorptive Clearance in the Cystic Fibrosis Airway

A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)

A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

R-2487 in Patients With Sjogren's Syndrome (SjD)

Gender-Responsive Treatment for Women Offenders - 1

Action Towards Health Equity and Improved Air Quality in the Duwamish Valley: A Multilevel Asthma Intervention

Gut Microbiome and p-Inulin in Hemodialysis

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

Food Effects of Single Oral Dose of 600mg TR-701